drugset / Trial / NCT01922258

Safety and Tolerability Study of Flexible Dosing of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type

NCT01922258 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To compare the efficacy of flexible dosing of brexpiprazole with placebo in subjects with agitation associated with dementia of the Alzheimer's type

Timeline

Start
2013-09
Primary completion
2017-03
Completion
2017-03

Outcome

Missed primary endpoint

registry p =0.1454; Treatment Difference -2.34 (95% CI -5.49 to 0.82) NCT01922258 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 0.5 mg —
Subject Brexpiprazole Small molecule 1 mg —
Subject Brexpiprazole Small molecule 2 mg —